Advanced Biologics announced the results of its most recent peer-reviewed data on the use of OsteoAMP for cervical spine fusions, which are also published in the Journal of Spine.
OsteoAMP is an allograft-derived growth factor that can be used as an alternative to recombinant growth factors, such as rhBMP-2 and allograft-derived stem cells, such as Osteocel Plus.
A retrospective analysis was conducted of 140 consecutive patients that had undergone cervical spine fusions using OsteoAMP. In dependent radiologists assessed fusion at 3 months, 6 months, 12 months and 18 months.
The study showed that 80 percent of patients had evidence of fusions at 6 months, 98 percent of patients had evidence of fusions at 12 months, and 100 percent of patients had evidence of fusions at 18 months.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws